128 related articles for article (PubMed ID: 10533903)
1. Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo.
Kajiwara T; Takeuchi T; Ueki T; Moriyama N; Ueki K; Kakizoe T; Kawabe K
Int J Urol; 1999 Oct; 6(10):520-5. PubMed ID: 10533903
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
3. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.
Beham AW; Sarkiss M; Brisbay S; Tu SM; von Eschenbach AC; McDonnell TJ
Int J Mol Med; 1998 Jun; 1(6):953-9. PubMed ID: 9852630
[TBL] [Abstract][Full Text] [Related]
4. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
6. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage.
Lin Y; Fukuchi J; Hiipakka RA; Kokontis JM; Xiang J
Cell Res; 2007 Jun; 17(6):531-6. PubMed ID: 17404601
[TBL] [Abstract][Full Text] [Related]
8. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
9. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.
Zhang Y; Yu J; Unni E; Shao TC; Nan B; Snabboon T; Kasper S; Andriani F; Denner L; Marcelli M
Hum Gene Ther; 2002 Nov; 13(17):2051-64. PubMed ID: 12490000
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
11. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF
Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800
[TBL] [Abstract][Full Text] [Related]
13. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.
Nesslinger NJ; Shi XB; deVere White RW
Cancer Res; 2003 May; 63(9):2228-33. PubMed ID: 12727844
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
15. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
16. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
17. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Bruckheimer EM; Kyprianou N
Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
20. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
